Skip to content
Home/Companies/Biotech/Inozyme Pharma

Inozyme Pharma

Biotech·United States·Exited 2025·Held 2yr
Entry
2023
Hold
2yr
Exit
2025

Who owns Inozyme Pharma?

Inozyme Pharma is an American Biotech company, now owned by BioMarin Pharmaceutical, which acquired it in 2025 from Novo Holdings.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Novo Holdings
Investor
Novo Holdings
Novo Holdings Principal Investments · 1999 · Buyout

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
BioMarin Pharmaceutical
Exit Year
2025

More from Novo Holdings Principal Investments

Other portfolio companies in the same fund.

Tempus AI
Active
HealthTechUS· 2026
Benchmark Genetics
Active
AgTechUK· 2025
KalVista Pharmaceuticals
Active
PharmaUS· 2025
Schott Poonawalla
Active
IndustrialsIndia· 2025
Catalent
Active
PharmaUS· 2024
Manipal Hospitals
Active
HealthcareIndia· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Inozyme Pharma?

Inozyme Pharma is now owned by BioMarin Pharmaceutical, which acquired it in 2025 from Novo Holdings.

When did BioMarin Pharmaceutical acquire Inozyme Pharma?

BioMarin Pharmaceutical acquired Inozyme Pharma in 2025, buying from Novo Holdings.

Who did Inozyme Pharma sell to?

Novo Holdings sold Inozyme Pharma to BioMarin Pharmaceutical in 2025 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue